Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon

SOBRE EL AUTOR **

My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

Tuesday, October 26, 2021

Cellulitis & Dalbavancin

SGEM#348 - By admin - October 23, 2021
Reference: Talan et al. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. AEM October 2021
“CLINICAL QUESTION: DOES THE USE OF A CLINICAL PATHWAY, INCLUDING A DOSE OF INTRAVENOUS DALBAVANCIN, IN EMERGENCY DEPARTMENT PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS REDUCE HOSPITALIZATIONS?
Authors’ Conclusions: “Implementation of an ED SSTI clinical pathway for patient selection and follow-up that included use of a single-dose, long-acting IV antibiotic was associated with a significant reduction in hospitalization rate for stable patients with moderately severe infections.”
KEY RESULT: LESS PATIENTS WERE HOSPITALIZED AFTER THE IMPLEMENTATION OF THE NEW CLINICAL PATHWAY THAT INCLUDED A SINGLE-DOSE, LONG-ACTING IV ANTIBIOTIC.
SGEM BOTTOM LINE: IN HOSPITAL SYSTEMS WITH ACCESS TO IV DALBAVANCIN AND THE ABILITY TO ESTABLISH EXPEDITED TELEPHONE AND IN-PERSON FOLLOW UP, THIS CLINICAL PATHWAY IS ASSOCIATED WITH A DECREASE IN HOSPITALIZATIONS FOR PATIENTS WITH MODERATELY SEVERE CELLULITIS”